Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroblastoma × TPI-287 × Clear all
NCT00867568 2024-08-06

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Milton S. Hershey Medical Center

Phase 1 Completed
18 enrolled 12 charts
CNS

Medulloblastoma, Neuroblastoma, Recurrence

NCT01483820 2024-08-06

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Milton S. Hershey Medical Center

Phase 1/2 Terminated
8 enrolled 9 charts
CNS

Medulloblastoma, Neuroblastoma

NCT01505608 2024-08-06

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Milton S. Hershey Medical Center

Phase 1/2 Terminated
14 enrolled 11 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡